You need to upgrade your Flash Player to view this content.
Hypoglycemia guidelines from ADA/Endocrine Society
New guidelines for preventing and managing hypoglycemia in patients with diabetes
New patient education handout: Healthful Living: Physical Activity
Discusses the importance of physical activity as part of an overall healthful living plan.
Clinical Insights® in Cardiovascular Disease
Latest issue: PCSK9 inhibitors for LDL-C lowering, statin therapy for LDL-C lowering in primary prevention, results from TRILOGY ACS, and more.
American Diabetes Association 2013 guidelines are here
View summary recommendations and accompanying slides on treatment and management topics featured in the 2013 ADA guidelines, including diabetes and CVD and diabetes and hypertension.
Niacin/laropiprant products to be suspended worldwide
The European Medicines Agency (EMA) has recommended that the marketing, supply, and authorizations of three niacin/laropiprant products—Tredaptive, Pelzont, and Trevaclyn—for the treatment of adults with dyslipidemia be suspended across the European Union. The manufacturer, Merck, is working with regulatory agencies in all countries to suspend the availability of the product. Click here for more information.
FDA announces label changes for statins
FDA has announced safety label changes for statins. Changes include removal of routine monitoring of liver enzymes from drug labels; information about potential for cognitive side effects and reports of increased blood sugar and A1C has been added. The lovastatin label has also been extensively updated.
Not a member? What are you waiting for?
Sign up now for exclusive access to downloadable slides and other content from CCMDweb.org. Registration is free and takes just a moment to complete.
CCMDweb.org: Professional Education
for Cardiovascular Disease
CCMDweb.org is a premier destination for professional education, clinically relevant information, and programs that augment knowledge and practice gaps in cardiovascular disease (CVD) with the goal of enhancing patient care. Since 1996, CCMD has partnered with preeminent thought leaders to educate US healthcare professionals on issues spanning the cardiovascular disease (CVD) spectrum—highlighting many cardiometabolic conditions that individually or collectively contribute to cardiovascular risk, including dyslipidemia, atherosclerosis, diabetes, stroke, inflammation, and obesity.
A sample of the award-winning programs on CCMDweb.org:
- Slide library with nearly 1,000 downloadable slides exploring cardiometabolic diseases
- On-demand programs, including newsletters, case studies, and webcasts
- Clinical guidelines resources
- Expert commentaries on seminal research
- Patient education handouts
- And more!
Registration is free and unlocks premium content offerings and incentives. Sign up here
CCMDweb.org is the official website of The Committee on Cardiovascular and Metabolic Diseases™ (CCMD™), a multi-component independent educational initiative offering programs and resources focused on the management of cardiovascular and metabolic diseases as a means to prevent or reduce global cardiovascular risk. Click here
for more information about CCMD.